Wellness Franchise Opportunities

MedicineNov, 11 2014

New drug brings hope for patients suffering from common liver disease.

People with non-alcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had felt improved liver health during that duration, which also include fat in the liver, decreased body weight and inflammation in comparison with those who receive a placeb

By WI Bureau

 

A clinical trial in the US has received an experimental drug that aimed at treating a common liver disease with promising results.

As per a report of leading business daily, The Economic Times, people with non-alcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had felt improved liver health during that duration, which also include fat in the liver, decreased body weight and inflammation in comparison with those who receive a placebo. This was ostensibly showed in the findings of the Farnesoid X Receptor Ligand Obeticholic Acid or FLINT in NASH treatment trial.

The report also stated that Brent Neuschwander-Tetri, professor at the St. Louis University in the US noted, "The FLINT trial represents an important advance in the search for treatments for NASH. The causes of NASH are not fully understood, and causes and treatments may be different among patients.”

The major feature of NASH is fat along with inflammation and damage in the liver. As the time passes, these health issues may lead to loss of liver function, the need for liver transplant and death, in some extreme cases.

The ET report also mentioned that Averell Sherker from the National Institute of Diabetes and Digestive and Kidney Diseases has said,"Although obeticholic acid did not eliminate liver disease in FLINT participants, it demonstrated a promising effect. Larger studies will be required to determine the drug's safety and efficacy.”

About 283 people were enrolled at 80 centres across the country for the study of NASH. The findings were published online in The Lancet.

Related: Rajya Sabha members seek govt intervention on essential medicines price hike

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.


Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.